FRLN(Delisted)
FreelineยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FRLN
Freeline Therapeutics Holdings Plc
A clinical-stage biotechnology company that developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies
--
04/03/2020
08/07/2020
NASDAQ Stock Exchange
152
12-31
Depository Receipts (Ordinary Shares)
Sycamore House, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2BP, United Kingdom
--
Freeline Therapeutics Holdings Plc was incorporated in England and Wales on April 3, 2020. The company is a clinical-stage, fully integrated next-generation system-based AAV gene therapy company that aims to transform the lives of patients with inherited systemic debilitating diseases. The company aims to provide one-time gene therapy, which can be achieved through a proprietary gene therapy platform, providing functional treatment through permanent and continuous physiological protein levels.
Company Financials
EPS
FRLN has released its 2023 Q3 earnings. EPS was reported at -0.18, versus the expected -0.23, beating expectations. The chart below visualizes how FRLN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FRLN has released its 2023 Q2 earnings report, with revenue of 617.00K, reflecting a YoY change of NaN%, and net profit of -16.01M, showing a YoY change of 34.24%. The Sankey diagram below clearly presents FRLN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
